| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7541350 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US6858596 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9320862 | GLAXOSMITHKLINE | Fluid dispensing device |
Nov, 2024
(6 months from now) | |
| US8147461 | GLAXOSMITHKLINE | Fluid dispensing device |
Mar, 2025
(10 months from now) | |
| US8062264 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8752543 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8347879 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2027
(2 years from now) | |
Veramyst is owned by Glaxosmithkline.
Veramyst contains Fluticasone Furoate.
Veramyst has a total of 8 drug patents out of which 3 drug patents have expired.
Expired drug patents of Veramyst are:
- US7541350
- US7101866
- US6858596
Veramyst was authorised for market use on 27 April, 2007.
Veramyst is available in spray, metered;nasal dosage forms.
Veramyst can be used as treatment of rhinitis comprising the nasal application of a pharmaceutical formulation as claimed in us patent 7541350, the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older.
The generics of Veramyst are possible to be released after 01 April, 2027.
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Treatment of rhinitis comprising the nasal application of a pharmaceutical formulation as claimed in us patent 7541350; The treatment of the symptoms of seasonal and perennial allergic rhinitis in pat...
Dosage: SPRAY, METERED;NASAL
VERAMYST family patents
